Purpose The objective of this study was to determine whether the addition of trastuzumab to
chemotherapy in the neoadjuvant setting could increase pathologic complete response
(pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)–positive
disease. Patients and Methods Forty-two patients with HER2-positive disease with operable
breast cancer were randomly assigned to either four cycles of paclitaxel followed by four
cycles of fluorouracil, epirubicin, and cyclophosphamide or to the same chemotherapy with …

Significantly higher pathologic complete remission rate after neoadjuvant therapy with
trastuzumab, paclitaxel, and epirubicin chemotherapy : results of a ramdomized trial in
human epidermal growth factor receptor 2-positive operable breast cancer | CiNii Research …
Significantly higher pathologic complete remission rate after neoadjuvant therapy with
trastuzumab, paclitaxel, and epirubicin chemotherapy : results of a ramdomized trial in
human epidermal growth factor receptor 2-positive operable breast cancer …